Laboratory

Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers

Retrieved on: 
星期四, 五月 2, 2024
Neoplasm, Medication, Cancer, Laboratory, Bias, Innovation, Big Pharma, University of Oxford, Octopus Group, Health care, Recurrence, Kindred, Vaccine, CRUK, Cancer Research Institute, Patient, LC-MS/MS, MHRA, Immune system, Associate, Precision, Growth

OXFORD, England, May 2, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the completion of a £12.8m seed funding round led by Octopus Ventures.  The round was heavily oversubscribed, also drawing in funds from Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital, Wilbe Capital, and expert angel investors. The total funds raised combine new equity investment and a prestigious non-dilutive award from Innovate UK's Future Economy Investor Partnership scheme.

Key Points: 
  • Since incorporation in 2021, Infinitopes has moved swiftly to cement its leadership position in cancer vaccines by overcoming three key challenges in the field.
  • Firstly, using its Precision ImmunomicsTM antigen discovery technologies, the Company can identify and rank tumour signatures, without prior bias, enabling the accurate selection of novel, synergistic tumour targets.
  • Secondly, Infinitopes continues to develop safe and effective, proprietary vector delivery systems, capable of stimulating durable T-cell responses necessary to prevent the recurrence of life-threatening cancer metastases.
  • Infinitopes' lead asset, a novel cancer vaccine called ITOP1, is scheduled to commence a phase I/IIa study in first line cancer patients in the third quarter of 2024.

EY Announces Charles Zhang and Lynn Chen-Zhang of Zhang Financial as an Entrepreneur Of The Year® 2024 Michigan and Northwest Ohio Award Finalist

Retrieved on: 
星期三, 五月 1, 2024
Courage, Probability, Woman, EY, Laboratory, Entrepreneurship, Philosophy, Growth, Ernst & Young

PORTAGE, Mich., May 1, 2024 /PRNewswire/ -- Ernst & Young LLP (EY US) recently announced that Charles Zhang, Founder and President and Lynn Chen-Zhang, CEO of Zhang Financial were named as finalists for the Entrepreneur Of The Year® 2024 Michigan and Northwest Ohio Award. Now in its 38th year, Entrepreneur Of The Year is the preeminent competitive business award for audacious leaders who disrupt markets, revolutionize sectors and have a transformational impact on lives. Over the past four decades, the program has recognized the daring entrepreneurs with big ideas and bold actions that reshape our world.

Key Points: 
  • PORTAGE, Mich., May 1, 2024 /PRNewswire/ -- Ernst & Young LLP (EY US) recently announced that Charles Zhang, Founder and President and Lynn Chen-Zhang, CEO of Zhang Financial were named as finalists for the Entrepreneur Of The Year® 2024 Michigan and Northwest Ohio Award .
  • Over the past four decades, the program has recognized the daring entrepreneurs with big ideas and bold actions that reshape our world.
  • Charles and Lynn were part of 34 regional entrepreneurs from 30 companies selected as finalists by an independent panel of judges .
  • Founded and produced by Ernst & Young LLP, the Entrepreneur Of The Year Awards include presenting in Michigan and Northwest Ohio, sponsors also include Full View Productions, KLA Laboratories Inc., P.I.E.

Global Functional Dyspepsia Drug Market to reach a valuation of US$ 16.4 billion by 2034, Future Market Insights, Inc. Projection

Retrieved on: 
星期三, 五月 1, 2024
Gastroenterology, Transplant, Acupuncture, Indigestion, Research, Laboratory, Probiotic, Abbott Laboratories, Herbal, Therapy, Patient, Tissue engineering, Enzyme inhibitor, Regenerative medicine, Collaboration, Market, Diagnosis, Antacid, Drug development, Regeneration, Ageing, Investment, Nutritional science, Pharmaceutical industry

NEWARK, Del., May 1, 2024 /PRNewswire/ -- The global functional dyspepsia drug market will reach a valuation of US$ 10.3 billion in 2024, attributed to factors such as increasing geriatric population. The trend is set to create new opportunities for the market, leading to a projected CAGR of 4.8% between 2024 and 2034, and reaching a total valuation of approximately US$ 16.4 billion by 2034.

Key Points: 
  • NEWARK, Del., May 1, 2024 /PRNewswire/ -- The global functional dyspepsia drug market will reach a valuation of US$ 10.3 billion in 2024, attributed to factors such as increasing geriatric population.
  • Collaboration between pharmaceutical companies, academic institutions, and research organizations fosters innovation in functional dyspepsia drug development.
  • Key Takeaways from the Market Study:
    Global functional dyspepsia drug market was valued at US$ 9.7 billion in 2023.
  • The functional dyspepsia drug market is characterized by a diverse array of pharmaceutical companies, research institutions, and healthcare organizations striving to develop and commercialize innovative treatments for functional dyspepsia.

Global Functional Dyspepsia Drug Market to reach a valuation of US$ 16.4 billion by 2034, Future Market Insights, Inc. Projection

Retrieved on: 
星期三, 五月 1, 2024
Gastroenterology, Transplant, Acupuncture, Indigestion, Research, Laboratory, Probiotic, Abbott Laboratories, Herbal, Therapy, Patient, Tissue engineering, Enzyme inhibitor, Regenerative medicine, Collaboration, Market, Diagnosis, Antacid, Drug development, Regeneration, Ageing, Investment, Nutritional science, Pharmaceutical industry

NEWARK, Del., May 1, 2024 /PRNewswire/ -- The global functional dyspepsia drug market will reach a valuation of US$ 10.3 billion in 2024, attributed to factors such as increasing geriatric population. The trend is set to create new opportunities for the market, leading to a projected CAGR of 4.8% between 2024 and 2034, and reaching a total valuation of approximately US$ 16.4 billion by 2034.

Key Points: 
  • NEWARK, Del., May 1, 2024 /PRNewswire/ -- The global functional dyspepsia drug market will reach a valuation of US$ 10.3 billion in 2024, attributed to factors such as increasing geriatric population.
  • Collaboration between pharmaceutical companies, academic institutions, and research organizations fosters innovation in functional dyspepsia drug development.
  • Key Takeaways from the Market Study:
    Global functional dyspepsia drug market was valued at US$ 9.7 billion in 2023.
  • The functional dyspepsia drug market is characterized by a diverse array of pharmaceutical companies, research institutions, and healthcare organizations striving to develop and commercialize innovative treatments for functional dyspepsia.

Seven Corporate Buyers Enter Into Aggregation Deal To Purchase 180 MW of Solar Energy Through the Net Zero Consortium for Buyers

Retrieved on: 
星期三, 五月 1, 2024
Negotiation, Sustainable business, Cisco, Sustainability, Laboratory, Health, Software, Partnership, Electricity, ERCOT, Research, VPPA, Gamer, Bio-Rad Laboratories, Idexx Laboratories, Duke Energy, Multimedia, Cadence Design Systems, PTC, Renewable energy

The seven buyers signed VPPAs to develop new renewable energy capacity in the ERCOT region of Texas through SR Inc's NZCB.

Key Points: 
  • The seven buyers signed VPPAs to develop new renewable energy capacity in the ERCOT region of Texas through SR Inc's NZCB.
  • The buyer-aggregated approach democratizes access to the commercial and environmental benefits of utility-scale renewable energy by making procurement accessible to a broader range of enterprises.
  • Finally, a large healthcare company will purchase renewable energy generated from the remaining 20 MW portion of Millers Branch.
  • SR Inc's Net Zero Consortium for Buyers (NZCB) is a confidential buyers' community committed to creating corporate buyer-favorable renewable energy transactions that enable participating enterprises to chart a profitable path to Net Zero emissions globally.

Southern Power expands Millers Branch Solar Facility in Texas

Retrieved on: 
星期三, 五月 1, 2024
Phase, Cisco, Laboratory, PTC, Guarantee of origin, Wind, Procurement, Idexx Laboratories, Renewable energy

ATLANTA, May 1, 2024 /PRNewswire/ -- Southern Power, a leading U.S. wholesale energy provider and subsidiary of Southern Company, today announced the expansion of its 29th solar project — Millers Branch Solar Facility.

Key Points: 
  • ATLANTA, May 1, 2024 /PRNewswire/ -- Southern Power, a leading U.S. wholesale energy provider and subsidiary of Southern Company, today announced the expansion of its 29th solar project — Millers Branch Solar Facility.
  • "We are thrilled to announce the expansion of our Millers Branch Solar Facility," said Southern Power President Robin Boren.
  • Southern Power will lead the continued development and construction of both phases of Millers Branch.
  • With the addition of Millers Branch Phase II, Southern Power's solar portfolio consists of more than 2,920 MW of solar generation currently operating or under construction.

Neogen® Petrifilm® Celebrates 40 Years!

Retrieved on: 
星期三, 五月 1, 2024
Food safety, Product design, Laboratory, Neogen, Red, Gold

LANSING, Mich., May 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) is celebrating 40 years of Petrifilm, the innovation that changed how microbiologists around the world perform indicator testing.

Key Points: 
  • LANSING, Mich., May 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) is celebrating 40 years of Petrifilm, the innovation that changed how microbiologists around the world perform indicator testing.
  • "In the food safety industry, Petrifilm is recognized as a true game-changer," said John Adent , Neogen's President and CEO.
  • Introduced in 1984, Petrifilm eliminates the need for traditional agar preparation, saving time and offering consistent, uniform testing media.
  • *
    As the first dry-film plate technology, Petrifilm revolutionized the way laboratories operate, putting the focus on quality and efficiency.

Neogen® Petrifilm® Celebrates 40 Years!

Retrieved on: 
星期三, 五月 1, 2024
Food safety, Product design, Laboratory, Neogen, Red, Gold

LANSING, Mich., May 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) is celebrating 40 years of Petrifilm, the innovation that changed how microbiologists around the world perform indicator testing.

Key Points: 
  • LANSING, Mich., May 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) is celebrating 40 years of Petrifilm, the innovation that changed how microbiologists around the world perform indicator testing.
  • "In the food safety industry, Petrifilm is recognized as a true game-changer," said John Adent , Neogen's President and CEO.
  • Introduced in 1984, Petrifilm eliminates the need for traditional agar preparation, saving time and offering consistent, uniform testing media.
  • *
    As the first dry-film plate technology, Petrifilm revolutionized the way laboratories operate, putting the focus on quality and efficiency.

Shineco Develops Revolutionary New Product with Varied Applications to Positively Impact the Health Care Industry

Retrieved on: 
星期三, 五月 1, 2024
Conditional sentence, Brain, Drug, Enzyme, Patient, Bone marrow, Acetone, Organelle, Soybean, Inflammation, Methane, Protein, Cell, Laboratory, Mineral, Pregnancy, Blood, Yolk, Health, Apoptosis, Human body, Death, Research, Vitamin, Water, Carbon, Functional food, Phospholipid, Kaifeng, Dietary fiber, Disease, Convalescence, Agonal respiration, Human, Mitochondrion, SISI, Food, Medicine, PC, Golgi, Carbohydrate, Nutrient, Beauty, Signal transduction, Temperature, Ageing, Microsome, Lipid, Cell damage, Malabsorption, Growth, Fats, Phosphorus

Cells are the basic units of life, and the health and vitality of cells directly affect the health of the entire body.

Key Points: 
  • Cells are the basic units of life, and the health and vitality of cells directly affect the health of the entire body.
  • Cells need to continuously obtain nutrients from the external environment to support their normal growth, division and metabolic activities.
  • When cells receive sufficient and balanced nutrients, they can maintain optimal conditions, perform various life activities, and maintain cell health.
  • The layout of the three major fields will create natural active water phospholipids into a super new category in the health industry.

Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers

Retrieved on: 
星期二, 四月 30, 2024
Neoplasm, Medication, Cancer, Laboratory, Bias, Innovation, Big Pharma, University of Oxford, Octopus Group, Health care, Recurrence, Kindred, Vaccine, CRUK, Cancer Research Institute, Patient, LC-MS/MS, MHRA, Immune system, Associate, Precision, Growth

OXFORD, England, April 30, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the completion of a £12.8m seed funding round led by Octopus Ventures.  The round was heavily oversubscribed, also drawing in funds from Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital, Wilbe Capital, and expert angel investors. The total funds raised combine new equity investment and a prestigious non-dilutive award from Innovate UK's Future Economy Investor Partnership scheme.

Key Points: 
  • Since incorporation in 2021, Infinitopes has moved swiftly to cement its leadership position in cancer vaccines by overcoming three key challenges in the field.
  • Firstly, using its Precision ImmunomicsTM antigen discovery technologies, the Company can identify and rank tumour signatures, without prior bias, enabling the accurate selection of novel, synergistic tumour targets.
  • Secondly, Infinitopes continues to develop safe and effective, proprietary vector delivery systems, capable of stimulating durable T-cell responses necessary to prevent the recurrence of life-threatening cancer metastases.
  • Infinitopes' lead asset, a novel cancer vaccine called ITOP1, is scheduled to commence a phase I/IIa study in first line cancer patients in the third quarter of 2024.